Scisparc's drug discovery joint venture mitocarex bio successfully developed its core algorithm to allow suitable modelling of human mitochondrial carriers for accelerating its cancer drug discovery program

Tel aviv, israel, may 08, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (“company” or “scisparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its joint venture mitocarex bio , which focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3d comparative models of human slc25a mitochondrial carrier proteins - promising transporting targets for innovating therapies.
SPRC Ratings Summary
SPRC Quant Ranking